Analysis of plasmin generation and clot lysis of plasma fibrinogen purified from a heterozygous dysfibrinogenemia, BβGly15Cys (Hamamatsu II)

Blood Coagulation and Fibrinolysis

Volumn 20, Issue 8, 2009, Pages 726-732

  Kamijyo, Yuka ^a   Hirota Kawadobora, Masako ^a   Yamauchi, Kazuyoshi ^a   Terasawa, Fumiko ^b   Honda, Takayuki ^c   Ikeya, Manae ^d   Okumura, Nobuo ^b  

^a SHINSHU UNIVERSITY HOSPITAL   (Japan)

^b SHINSHU UNIVERSITY   (Japan)

^c SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Seirei Mikatagahara Hospital   (Japan)

Author keywords

Albumin binding form; Bb chain; Clot lysis; Dysfibrinogen; Infarction of the medulla oblongata; Plasmin generation

Indexed keywords

ALBUMIN; DODECYL SULFATE; FIBRINOGEN; PLASMIN; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ARTERY THROMBOSIS; ARTICLE; ATAXIA; BLOOD CLOT LYSIS; BLOOD CLOTTING TEST; BLOOD SAMPLING; CASE REPORT; CHILD; DNA DETERMINATION; DNA SEQUENCE; DYSFIBRINOGENEMIA; FIBRIN POLYMERIZATION; FIBRINOGEN BLOOD LEVEL; GENETIC POLYMORPHISM; HAMAMATSU II; HEADACHE; HUMAN; HYPERHOMOCYSTEINEMIA; ILLUSION; IMMUNOAFFINITY CHROMATOGRAPHY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMINOGEN ACTIVATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN POLYMERIZATION; SCANNING ELECTRON MICROSCOPY; SCHOOL CHILD; SENSORY DYSFUNCTION;

AFIBRINOGENEMIA; CHILD; FIBRINOGENS, ABNORMAL; FIBRINOLYSIN; FIBRINOLYSIS; HETEROZYGOTE; HUMANS; MALE; PLASMINOGEN; THROMBOSIS;

EID: 70449586782     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328332aa09     Document Type: Article

References (30)

1. Doolittle RF, Bouma IH, Cottrell BA, Strong D, Watt KWK. The covalent structure of human fibrinogen. In: Bing DH, editor. The chemistry and physiology of the human plasma proteins. New York: Pergamon Press; 1979. pp. 77-95.
2. Doolittle RF. Fibrinogen and fibrin. Sci Am 1981; 245:92-101.
3. Weisel JW. Fibrinogen and fibrin. Adv Protein Chem 2005; 70:247-299.
4. Hanss ML, Biot F. Fibrinogen variants. http://www.geht.org/databaseang/ fibrinogen [Accessed 30 January 2009].
5. Haverkate S, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC subcommittee on fibrinogen. Thromb Haemost 1995; 73:151-161.
6. Hirota-Kawadobora M, Terasawa F, Yonekawa O, Shara N, Shimizu E, Okumura N, et al. Fibrinogens Kosai and Ogasa: Bb15Gly!Cys (GGT!TGT) substitution associated with impairment of fibrinopeptide B release and lateral aggregation. J Thromb Haemost 2003; 1:275-283.
7. Hirota-Kawadobora M, Kani S, Terasawa F, Fujihara N, Yamauchi K, Tozuka M, et al. Functional analysis of recombinant Bb15C and Bb15A fibrinogens demonstrates that Bb15G residue plays important roles in FPB release and in lateral aggregation of protofibrils. J Thromb Haemost 2005; 3:983-990.
8. Yoshida N, Wada H, Morita K, Hirata H, Matsuda M, Yamazumi K, et al. A new congenital abnormal fibrinogen Ise characterized by the replacement of Bb glycine-15 by cystein. Blood 1991; 77:1958-1963.
9. Kamura T, Tsuda H, Yae Y, Hattori S, Ohga S, Shibata Y, et al. An abnormal fibrinogen Fukuoka II (Gly-Bb!15Cys) characterized by defective fibrin lateral association and mixed disulfide formation. J Biol Chem 1995; 270:29392-29399.
10. Kaudewitz H, Henschen A, Soria C, Soria J, Bertrand O, Heaton D. The molecular defect of the genetically abnormal fibrinogen Christchurch II. In: Muller-Berghaus G, Scheefers-Brochel V, Sellmayn E, Henschen A, editors. Fibrinogen and its derivatives. Amsterdam: Elsevier Science Publishers BV; 1986. pp. 31-37.
11. Pirkle H, Kaudewitz H, Henschen A, Theodor I, Simmons G. Substitution of Bb 14 arginine by cyst(e)ine in fibrinogen Seattle I. In: Lowe GDO, Douglas JT, Forbes CD, Henschen A, editors. Fibrinogen 2. Biochemistry, physiology and clinical relevance. Amsterdam: Elsevier Science Publishers BV; 1987. pp. 49-52.
12. Koopman J, Haverkate F, Grimbergen J, Engesser L, Novakova I, Kerst AFJA, et al. Abnormal fibrinogen Ijmuiden (BbArg14!Cys) and Nijmegen (BbArg44!Cys) form disulfide-linked fibrinogen-albumin complexes. Proc Natl Acad Sci U S A 1992; 89:3478-3482.
13. Brennan SO, Hammonds B, Spearing R, George PM. Electrospray ionisation mass spectrometry facilitates detection of fibrinogen (Bb14Arg!Cys) mutation in a family with thrombosis. Thromb Haemost 1997; 78:1484-1487.
14. Vakalopoulou S, Mille-Baker B, Mumford A, Manning R, Laffan M. Fibrinogen Bb14 Arg!Cys: further evidence for a role in thrombosis. Blood Coagul Fibrinolysis 1999; 10:403-408.
15. Castaman G, Ghiotto R, Tosetto A, Rodeghiero F. Bb14Arg!Cys variant dysfibrinogen and its association with thrombosis. J Thromb Haemost 2005; 3:409-410.
16. De Raucourt E, Fisher AM, Meyer GA, De Mazancourt P. A Bb14Arg!Cys fibrinogen variant in a patient with thrombotic complications (fibrinogen St-Germain III). J Thromb Haemost 2006; 4:2722-2723.
17. Terasawa F, Okumura N, Kitano K, Hayashida N, Shimosaka M, Okazaki M, et al. Hypofibrinogenemia associated with a heterozygous missense mutation g153Cys to Arg (Matsumoto IV): In vitro expression demonstrates defective secretion of the variant fibrinogen. Blood 1999; 94:4122-4131.
18. Terasawa F, Kani S, Hongo M, Okumura N. In vitro fibrin clot formation and fibrinolysis using heterozygous plasma fibrinogen from gAsn319,Asp320 deletion dysfibrinogen, Otsu I. Thromb Res 2006; 118:651-661.
19. Okumura N, Haneishi A, Terasawa F. Citrullinated fibrinogen shows defects in FPA and FPB release and fibrin polymerization catalyzed by thrombin. Clin Chim Acta 2009; 401:119-123.
20. Takebe M, Soe G, Kohno I, Sugo T, Matsuda M. Calcium ion-dependent monoclonal antibody against human fibrinogen; preparation, characterization, and application to fibrinogen purification. Thromb Haemost 1995; 73:662-667.
21. Holm B, Nilsen DWT, Kierulf P, Godal HC. Purification and characterization of 3 fibrinogens with different molecular weights obtained from normal human plasma. Thromb Res 1985; 37:165-176.
22. Collet J-P, Soria J, Mirshahi M, Hirsch M, Dagonnet FB, Caen J, et al. Dusart syndrome: A new concept of the relationship between fibrin clot architecture and fibrin clot degradability - hypofibrinolysis related to an abnormal clot structure. Blood 1993; 82:2462-2469.
23. Carr ME Jr, Carr SL, Merten SR. Effects of ionic and nonionic contrast media on clot structure, platelet function and thrombolysis mediated by tissue plasminogen activator in plasma clots. Haemostasis 1995; 25:172-181.
24. Mullin JL, Norfolk SE, Weisel JW, Lord ST. Clot lysis of variant recombinant fibrinogens confirms that fiber diameter is a major determinant of lysis rate. Ann NY Acad Sci 2001; 936:331-334.
25. Doolittle RF, Pandi L. Binding of synthetic knobs to fibrinogen changes the character of fibrin and inhibits its ability to activate tissue plasminogen activator and its destruction by plasmin. Biochemistry 2006; 45:2657-2667.
26. Soria J, Soria C, Caen J-P. A new type of congenital dysfibrinogenaemia with defective fibrin lysis - Dusard syndrome: Possible relation to thrombosis. Br J Haematol 1983; 53:575-586.
27. Lijnen HR, Soria J, Soria C, Collen D, Caen JP. Dysfibrinogenemia (fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activation. Thromb Haemost 1984; 51:108-109.
28. Koopman J, Haverkate F, Grimbergen J, Lord ST, Mosesson MW, DiOrio JP, et al. Molecular basis for fibrinogen Dusart (Aa554Arg!Cys) and its association with abnormal fibrin polymerization and thrombophilia. J Clin Invest 1993; 91:1637-1643.
29. Collet J-P, Woodhead JL, Soria J, Soria C, Mirshahi M, Caen JP, et al. Fibrinogen Dusart: Electron microscopy of molecules, fibers and clots, and viscoelastic properties of clots. Biophys J 1996; 70:500-510.
30. Mosesson MW, Siebenlist KR, Hainfeld JF, Wall JS, Soria J, Soria C, et al. The relationship between the fibrinogen D domain self-association/ crosslinking site (gXL) and the fibrinogen Dusart abnormality (AaR554Calbumin). Clues to thrombophilia in the 'Dusart syndrome'. J Clin Invest 1996; 97:2342-2350.